UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The development of thermoplastic fibre based reinforcements for the rotational moulding process

AIP conference proceedings, 2018, Vol.1960 (1)

2018

Volltextzugriff (PDF)

Deriving Pandemic Disease Mitigation Strategies by Mining Social Contact Networks

Optimization, Control, and Applications in the Information Age, p.359-381

Volltextzugriff (PDF)

Lipoproteins in Diabetes Mellitus

Second edition, 2023

Volltextzugriff (PDF)

A collectivist conception of democracy (BL)

Mena Aleman, D

2001

Volltextzugriff (PDF)

A Simulation Case Study to Improve Staffing Decisions at Mass Immunization Clinics for Pandemic Influenza

Operational Research for Emergency Planning in Healthcare: Volume 1, p.190-223

Volltextzugriff (PDF)

A Requirements Catalog of Mobile Personal Health Records for Prenatal Care

Computational Science and Its Applications – ICCSA 2019, p.483-495

Volltextzugriff (PDF)

Anamnestic expansion of Omicron-reactive CD8 +T cells after booster SARS-CoV-2 mRNA vaccination across different immunocompromised states

JOURNAL OF IMMUNOLOGY, 2023, Vol.210 (1_Supplement), p.75-75.16

2023

Volltextzugriff (PDF)

Continued treatment of early non-responder or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis D through week 96 leads to improvement in virologic and biochemical responses

JOURNAL OF HEPATOLOGY, 2023, Vol.78, p.S113-S114

2023

Volltextzugriff (PDF)

Relationship of hepatitis D viral load, ALT levels, and liver stiffness in untreated patients with chronic hepatitis D

JOURNAL OF HEPATOLOGY, 2023, Vol.78, p.S1091-S1093

2023

Volltextzugriff (PDF)

The Nuc-Stop study: an open-label, randomized trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B patients

JOURNAL OF HEPATOLOGY, 2023, Vol.78, p.S1150-S1151

2023

Volltextzugriff (PDF)

Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks

JOURNAL OF HEPATOLOGY, 2022, Vol.77, p.S103

2022

Volltextzugriff (PDF)

Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta

JOURNAL OF HEPATOLOGY, 2022, Vol.77, p.S828

2022

Volltextzugriff (PDF)

Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta

JOURNAL OF HEPATOLOGY, 2022, Vol.77, p.S829

2022

Volltextzugriff (PDF)

Efficacy of bulevirtide as monotherapy for chronic hepatitis delta: Week 48 results from an integrated analysis

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, Vol.38, p.69

2023

Volltextzugriff (PDF)

CONTINUED TREATMENT OF EARLY NONRESPONDER OR PARTIAL VIROLOGIC RESPONDERS WITH BULEVIRTIDE MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS DELTA (CHD) THROUGH WEEK 96 LEADS TO IMPROVEMENT IN VIROLOGIC AND BIOCHEMICAL RESPONSES

GUT, 2023, Vol.72 (SUPPL_3), p.A101

2023

Volltextzugriff (PDF)

NO DETECTABLE RESISTANCE TO BULEVIRTIDE MONOTHERAPY THROUGH 96 WEEKS TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS D

HEPATOLOGY, 2023, Vol.78, p.S398

2023

Volltextzugriff (PDF)

EFFICACY OF BULEVIRTIDE AS MONOTHERAPY FOR CHRONIC HEPATITIS D (CHD): WEEK 48 RESULTS FROM AN INTEGRATED ANALYSIS

HEPATOLOGY, 2022, Vol.76, p.S228

2022

Volltextzugriff (PDF)

Slice Estimation in Diffusion MRI of Neonatal and Fetal Brains in Image and Spherical Harmonics Domains Using Autoencoders

Computational Diffusion MRI, p.3-13

Volltextzugriff (PDF)

GMP compliance for production of CB.Hep-1monoclonal antibody as a biological reagent

Biopharm international, 2006-02, Vol.19 (2), p.50

2006

Volltextzugriff (PDF)

Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis delta: An integrated safety analysis of 48-week data

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, Vol.38, p.70

2023

Volltextzugriff (PDF)

RELATIONSHIP BETWEEN ALT NORMALIZATION RATES AND DIFFERENT VIROLOGIC RESPONSE CRITERIA IN CHRONIC HDV PATIENTS TREATED WITH BULEVIRTIDE MONOTHERAPY

HEPATOLOGY, 2023, Vol.78, p.S586

2023

Volltextzugriff (PDF)

BASELINE CHARACTERISTICS OF HEPATITIS DELTA PATIENTS ENROLLED ACROSS PHASE 2 AND 3 STUDIES OF BULEVIRTIDE

HEPATOLOGY, 2023, Vol.78, p.S557

2023

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Aktive Filter

PublikationsformArtikel

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(72)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

The development of thermoplastic fibre based reinforcements for the rotational moulding process

Deriving Pandemic Disease Mitigation Strategies by Mining Social Contact Networks

Lipoproteins in Diabetes Mellitus

A collectivist conception of democracy (BL)

A Simulation Case Study to Improve Staffing Decisions at Mass Immunization Clinics for Pandemic Influenza

A Requirements Catalog of Mobile Personal Health Records for Prenatal Care

Anamnestic expansion of Omicron-reactive CD8 +T cells after booster SARS-CoV-2 mRNA vaccination across different immunocompromised states

Continued treatment of early non-responder or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis D through week 96 leads to improvement in virologic and biochemical responses

Relationship of hepatitis D viral load, ALT levels, and liver stiffness in untreated patients with chronic hepatitis D

The Nuc-Stop study: an open-label, randomized trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B patients

Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks

Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study

Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta

Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta

Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study

Efficacy of bulevirtide as monotherapy for chronic hepatitis delta: Week 48 results from an integrated analysis

CONTINUED TREATMENT OF EARLY NONRESPONDER OR PARTIAL VIROLOGIC RESPONDERS WITH BULEVIRTIDE MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS DELTA (CHD) THROUGH WEEK 96 LEADS TO IMPROVEMENT IN VIROLOGIC AND BIOCHEMICAL RESPONSES

CONTINUED TREATMENT OF EARLY VIROLOGIC NON-RESPONDER OR PARTIAL RESPONDERS WITH BULEVIRTIDE MONOTHERAPY FOR CHRONIC HEPATITIS D LEADS TO IMPROVEMENT IN VIROLOGIC AND BIOCHEMICAL RESPONSES: RESULTS FROM AN INTEGRATED ANALYSIS AT WEEK 96

NO DETECTABLE RESISTANCE TO BULEVIRTIDE MONOTHERAPY THROUGH 96 WEEKS TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS D

EFFICACY OF BULEVIRTIDE AS MONOTHERAPY FOR CHRONIC HEPATITIS D (CHD): WEEK 48 RESULTS FROM AN INTEGRATED ANALYSIS

Slice Estimation in Diffusion MRI of Neonatal and Fetal Brains in Image and Spherical Harmonics Domains Using Autoencoders

GMP compliance for production of CB.Hep-1monoclonal antibody as a biological reagent

Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis delta: An integrated safety analysis of 48-week data

RELATIONSHIP BETWEEN ALT NORMALIZATION RATES AND DIFFERENT VIROLOGIC RESPONSE CRITERIA IN CHRONIC HDV PATIENTS TREATED WITH BULEVIRTIDE MONOTHERAPY

BASELINE CHARACTERISTICS OF HEPATITIS DELTA PATIENTS ENROLLED ACROSS PHASE 2 AND 3 STUDIES OF BULEVIRTIDE

Aktive Filter

Suchergebnisse filtern